| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 07.02.
| Buy, Sell, or Hold: Geron | | 7 | Motley Fool |
| 06.02.
| Geron: Mea Culpa | | 5 | Seeking Alpha |
| 03.02.
| Geron concludes patient enrollment in cancer drug trial | | 5 | Pharma Bus Review |
| 20.01.
| Can Geron Recover in 2012? | | 51 | Motley Fool |
| 17.01.
| Notable Put Options Activity in Geron | | 7 | Benzinga.com |
| 11.01.
| Geron Corp Announces Phase 2 Data on Imetelstat Cancer Drug Won't be out Until Q4 2012 -Presentation Slides | | 12 | Benzinga.com |
| 05.01.
| Geron Corporation Appoints Graham Cooper as Chief Financial Officer | | 8 | Benzinga.com |
| 27.12.
| Geron Shares Rise 13% Pre-Market; May be Attributed to Positive Seeking Alpha Article | | 15 | Benzinga.com |
| 19.12.
| Price Hesitations for Geron Corporation (NASDAQ:GERN) Continue | | 8 | HotStocked.com |
| 12.12.
| Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer | | 33 | Business Wire |
| Geron Corporation (Nasdaq:GERN) today announced the initiation of
GRABM-B (GRN1005 Against Brain Metastases – Breast
cancer), a Phase 2 clinical trial to evaluate GRN1005...
Mehr lesen zu:
Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer | |
| 29.11.
| Geron Corporation and Keryx Biopharmaceuticals Making Ground in Lucrative Cancer Drug Market / The Paragon Report Provides Equity Research on Geron Corporation & Keryx Biopharmaceuticals | | 39 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 11/29/11 -- According to the World Health Organization, cancer will become the leading cause of death worldwide this year. Cancer has already emerged as the most expensive...
Mehr lesen zu:
Geron Corporation and Keryx Biopharmaceuticals Making Ground in Lucrative Cancer Drug Market / The Paragon Report Provides Equity Research on Geron Corporation & Keryx Biopharmaceuticals | |
| 28.11.
| Advanced Cell Technology and Cytori Therapeutics Gain Support as Geron Changes Strategy / The Paragon Report Provides Equity Research on Advanced Cell Technology & Cytori Therapeutics | | 205 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 11/28/11 -- The stem cell industry lost one of its key players earlier this month when industry pioneer, Geron Corporation announced its intention to exit the stem...
Mehr lesen zu:
Advanced Cell Technology and Cytori Therapeutics Gain Support as Geron Changes Strategy / The Paragon Report Provides Equity Research on Advanced Cell Technology & Cytori Therapeutics | |
| 21.11.
| InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes Strategy / The Bedford Report Provides Equity Research on InVivo Therapeutics & Cord Blood America | | 66 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 11/21/11 -- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell...
Mehr lesen zu:
InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes Strategy / The Bedford Report Provides Equity Research on InVivo Therapeutics & Cord Blood America | |
| 16.11.
| JPMorgan stuft Geron von Overweight auf Neutral ab. | | 78 | BörseGo |
| JPMorgan stuft Geron von Overweight auf Neutral ab.
(© BörseGo AG 2011 - Autor: Thomas Gansneder, Redakteur)
Mehr lesen zu:
JPMorgan stuft Geron von Overweight auf Neutral ab. | |
| 16.11.
| Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC | | 46 | Business Wire |
| Phase 2 Clinical Trials Will Be Initiated in Patients with Brain
Metastases
Geron Corporation (Nasdaq:GERN) today announced the final results of two...
Mehr lesen zu:
Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC | |
| 16.11.
| California Stem Cell's Hans Keirstead Weighs in on Geron News | | 190 | Business Wire |
| California Stem Cell, Inc. (CSC) announced today that despite recent
financial setbacks at Geron Corp., CSC's own stem cell therapeutic
programs remain financially viable...
Mehr lesen zu:
California Stem Cell's Hans Keirstead Weighs in on Geron News | |
| 15.11.
| UPDATE 1-Geron shares drop on stem cell retreat | | 5 | Reuters.com |
| 14.11.
| Geron (GERN) to Focus on Oncology Programs, Cancel Stem Cell Development Programs | | 1 | StreetInsider.com |
| 14.11.
| Geron (GERN) to focus on novel cancer programs, to discontinue development of stem cell programs, cutting 66 jobs | | 2 | StreetInsider.com |
| 14.11.
| Geron to Focus on Its Novel Cancer Programs | | 42 | Business Wire |
| Company Plans to Partner All Stem Cell Programs
Geron Corporation (Nasdaq: GERN) today announced that, effective
immediately, the Company will focus...
Mehr lesen zu:
Geron to Focus on Its Novel Cancer Programs | |
